Viragen Inc.
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

_____________________

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

January 30, 2003
Date of Report (Date of earliest event reported)

VIRAGEN, INC.

(Exact name of registrant as specified in its charter)

         
Delaware   001-15823   59-2101668
 
 
(State or other jurisdiction
of incorporation)		   (Commission File Number)   (IRS Employer
Identification No.)

865 SW 78th Avenue, Suite 100, Plantation, Florida 33324
(Address of principal executive offices)

(954) 233-8746
(Registrant’s telephone number, including area code)

Not Applicable
(Former name or former address, if changed since last report)

 

 

Item 5. Other Events

     On January 30, 2003, Viragen, Inc. announced that effective immediately Mr. Carl N. Singer will succeed Gerald Smith as Chairman of the Board of Directors and Mr. Robert C. Salisbury will succeed Mr. Smith as President and Chief Executive Officer. Mr. Smith will continue to serve on Viragen’s Board of Directors.

     A copy of the press release dated January 30, 2003 issued by the Company is filed as Exhibit 99.1 to this Current Report on
Form 8-K.

Item 7. Financial Statements and Exhibits

(c) Exhibits

     
99.1   Press Release dated January 30, 2003.

2

 

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     
    VIRAGEN, INC.
     
     
Date: January 30, 2003   By: /s/ Dennis W. Healey
   
    Dennis W. Healey
Executive Vice President and
Chief Financial Officer

3

 

Index to Exhibits

             
Exhibit No.   Exhibit Title        
 
       
99.1   Press Release dated January 30, 2003.

4